{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:48:55Z","timestamp":1760042935993},"reference-count":18,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":723,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> To determine whether ziprasidone alters the metabolizing activity of the 2D6 isoenzyme of cytochrome P450 (CYP2D6).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Twenty\u2010four healthy young subjects aged 18\u201345\u2003years were screened for CYP2D6 metabolizing activity and shown to be extensive metabolizers of dextromethorphan. These subjects were then randomized to receive a single dose of ziprasidone 80\u2003mg, paroxetine 20\u2003mg or placebo, 2\u2003h before receiving a dose of dextromethorphan. Urine samples for the determination of dextromethorphan concentrations were collected over the 8 h period following dextromethorphan dosing, and used for the determination of dextromethorphan\/dextrorphan ratios. Blood samples were collected immediately before and up to 10\u2003h after the administration of ziprasidone or paroxetine, and used to derive pharmacokinetic parameters of ziprasidone and paroxetine.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> There were no statistically significant changes in the urinary dextromethorphan\/dextrorphan ratio in the ziprasidone group or the placebo group. By contrast, there was a 10\u2010fold increase in the urinary dextromethorphan\/dextrorphan ratio in the paroxetine group and this differed significantly from those in the ziprasidone and placebo groups (<jats:italic>P<\/jats:italic>=\u20030.0001).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The findings of this study suggest that ziprasidone does not inhibit the clearance of drugs metabolized by CYP2D6.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00152.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:39:00Z","timestamp":1047357540000},"page":"43-47","source":"Crossref","is-referenced-by-count":15,"title":["Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers"],"prefix":"10.1111","volume":"49","author":[{"given":"K. D.","family":"Wilner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. B.","family":"Demattos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Anziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Apseloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"&","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"issue":"1","key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1046\/j.1365-2125.2000.00151.x","article-title":"Identification of the major human liver cytochrome P450 isoform responsible for the primary metabolites of ziprasidone and prediction of possible drug interactions","volume":"49","author":"Prakash C","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199615050-00004"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199612005-00005"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539508998329"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199500291-00004"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199308000-00004"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.1996.46"},{"key":"e_1_2_5_9_2","first-page":"820","article-title":"Serotonin reuptake inhibitors alter metabolism of clozapine","volume":"153","author":"Centorrhino F","year":"1996","journal-title":"Am J Psychiatry"},{"key":"e_1_2_5_10_2","first-page":"119","article-title":"Clozapine and metabolites: serum concentrations and clinical findings during treatment of chronically psychotic patients","volume":"4","author":"Centorrhino F","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_5_11_2","first-page":"3","volume":"64","author":"Metropolitan height and weight tables.","year":"1983","journal-title":"Stat Bull Metrop Life Found"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00071-P"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(87)80313-4"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(91)80203-L"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00147.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00148.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1989.tb07176.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1994.019.06.254341"},{"key":"e_1_2_5_19_2","first-page":"159","article-title":"Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential","volume":"4","author":"Tandon R","year":"1997","journal-title":"J Serotonin Res"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00152.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00152.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00152.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T18:02:52Z","timestamp":1698602572000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00152.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":18,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00152.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00152.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}